Nasdaq Rule 5810 — Deficiency Notice

Nasdaq Rule 5810 establishes the formal process Nasdaq follows when a listed company fails to meet its listing standards. When a deficiency is identified, Nasdaq issues a written notice beginning a prescribed cure period. Understanding this process — and acting strategically from day one of a deficiency — is essential for any micro-cap or de-SPAC company managing listing risk.

What Rule 5810 Governs

Rule 5810 defines the notification, cure, and hearing process that applies when Nasdaq determines a company is not in compliance with any of the listing standards found in Rules 5500–5600 (for the Nasdaq Capital Market) or 5400–5500 (for the Nasdaq Global Select Market). The most common deficiency triggers for micro-cap companies are:

• Minimum bid price — closing below $1.00 for 30 consecutive business days (Rule 5550(a)(2))
• Stockholders' equity — falling below $2.5M (Capital Market) or $10M (Global Select)
• Round-lot holders — fewer than the required minimum number of shareholders holding at least 100 shares
• Market value of listed securities — extended period below minimums
• Timely filing — failure to file SEC periodic reports on schedule

The Deficiency Process Timeline

• Day 0

  Nasdaq Issues Deficiency Notice

  Nasdaq sends a written notification (typically by certified mail) identifying the specific rule violation. The company must disclose the notice publicly via an 8-K filing within four business days. The notice is also published on Nasdaq's deficiency notification page.

• Day 1–180

  Initial Cure Period

  For bid price deficiencies, the company has 180 calendar days to regain compliance (price must close at or above $1.00 for 10 consecutive business days). For filing delinquencies, Nasdaq typically requires cure within 60 days or submission of a compliance plan. Other deficiency types have their own specific timelines.

• Day 181–360

  Second Cure Period (Bid Price Only)

  If the bid price deficiency is not cured in the first 180 days, a company may be eligible for a second 180-day period if it meets all other listing standards and notifies Nasdaq of its intent to cure via a reverse stock split if necessary. Not all companies qualify for the extension.

• Post-Period

  Delisting Determination or Hearing

  If the deficiency is not cured within the allowed period, Nasdaq issues a delisting determination. The company has seven calendar days to request a hearing before the Nasdaq Hearings Panel, which can grant additional time for a credible compliance plan.

Why It Matters for Micro-Caps

Receiving a Rule 5810 deficiency notice is a significant, market-moving event. The required 8-K disclosure of the notice typically triggers institutional selling as funds with minimum-bid-price or listing-status requirements are forced to exit the position. Short sellers often increase positions at the onset of a deficiency notice, anticipating further price pressure during the cure period.

The IR response to a deficiency notice matters enormously. Companies that communicate a clear, credible cure plan proactively — rather than waiting for Nasdaq deadlines — tend to retain more institutional support through the compliance process.

Deficiency Notices and the AxonIR Score

AxonIR monitors Nasdaq compliance signals as part of the AxonIR Score calculation. Companies with active deficiency notices or recent compliance cures carry adjusted scores reflecting elevated listing risk. Proactively curing deficiencies and demonstrating a recovery trajectory — through consistent filing cadence, improved algo-readability, and clear public communications — can improve the institutional visibility component of the score even during a compliance period.

Informational only — not legal or compliance advice. Consult Nasdaq-experienced securities counsel immediately upon receiving any deficiency notice. See our Disclaimer.